CAR T-Cell Therapy for Multiple Myeloma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Development

CAR T-Cell Therapy for Multiple Myeloma Pipeline Drugs and Companies Insight Report, 2023 Updates: Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Development
Las Vega (Nevada), United States //— As per DelveInsight’s assessment, globally, CAR T-Cell Therapy for Multiple Myeloma pipeline constitutes 5+ key companies continuously working towards developing 5+ CAR T-Cell Therapy for Multiple Myeloma treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

CAR T-Cell Therapy for Multiple Myeloma Overview

CAR T-cells, are the fusion proteins of a selected single-chain fragment variable from a specific monoclonal antibody and one or more T-cell receptor intracellular signalling domains. A CAR combines antigen-binding domains-most commonly, a single-chain variable fragment (scFv) derived from the variable domains of antibodies with the signaling domains of the TCR chain and additional costimulatory domains from receptors, such as CD28, OX40, and CD137.

 

CAR T-Cell Therapy for Multiple Myeloma Pipeline Insight, 2023 report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the CAR T-Cell Therapy for Multiple Myeloma Market.

 

The CAR T-Cell Therapy for Multiple Myeloma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

 

Some of the key takeaways from the CAR T-Cell Therapy for Multiple Myeloma Pipeline Report:

  • Companies across the globe are diligently working toward developing novel CAR T-Cell Therapy for Multiple Myeloma treatment therapies with a considerable amount of success over the years. CAR T-Cell Therapy for Multiple Myeloma Key players such as – Sana Biotechnology, Tmunity Therapeutics, Celyad Oncology, Cellectis, CRISPR Therapeutics, Carsgen Therapeutics, Autolus Limited, Eureka Therapeutics, CARsgen Therapeutics, Bellicum Pharmaceuticals, Tessa Therapeutics, CASI Pharmaceuticals, Cartesian Therapeutics, Miltenyi Biomedicine, and others, are developing therapies for the CAR T-Cell Therapy for Multiple Myeloma treatment 
  • CAR T-Cell Therapy for Multiple Myeloma Emerging therapies such as – SG295, GPC2 CAR-T, CYAD-203, UCART123, CTX110, CAR-GPC3, AUTO4, ET140202, Zevorcabtagene autoleucel, BPX-601, TT11, CNCT19, Descartes-08, MB-CART2019.1, and others are expected to have a significant impact on the CAR T-Cell Therapy for Multiple Myeloma market in the coming years.   
  • On January 10, 2022 Sana Biotechnology and Innovent Biologics announced that the companies entered into an agreement pursuant to which Sana obtained from IASO Bio and Innovent non-exclusive commercial rights to a clinically validated fully-human BCMA CAR construct for use in certain in vivo gene therapy and ex vivo hypoimmune cell therapy applications
  • In October 2021, IASO Biotherapeutics initiated a single-armed, open-label, multicenter Phase I/II study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM Leukapheresis procedure will be performed to manufacture CT103A chimeric antigen receptor (CAR) modified T cells
  • In February 2021, IASO Biotherapeutics and Innovent Biologics, announced that the Center for Drug Evaluation (CDE) of China’s National Medical Products Administration (NMPA) has granted Breakthrough Therapy Designation (BTD) for CT103A, an investigational chimeric antigen receptor (CAR)-T cell therapy co-developed by IASO Bio and Innovent (IASO Bio: CT103A, Innovent: IBI326), for treatment of relapsed/refractory multiple myeloma
  • In December 2021, Cartesian Therapeutics initiated a Phase II study of descartes-08 consolidation treatment in patients with high-risk multiple myeloma who have residual disease after induction therapy. The objective of the trial is to assess Minimal Residual Disease (MRD)-negative Complete Response (sCR) rate after consolidation treatment with Descartes-08 in patients with high-risk myeloma who have residual disease following induction therapy

 

Route of Administration

CAR T-Cell Therapy for Multiple Myeloma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

  • Subcutaneous
  • Intravenous
  • Oral
  • Intramuscular
  • Molecule Type

 

Molecule Type

Products have been categorized under various Molecule types, such as

  • Small molecules
  • Natural metabolites
  • Monoclonal antibodies
  • Product Type

 

CAR T-Cell Therapy for Multiple Myeloma Pipeline Therapeutics Assessment

  • CAR T-Cell Therapy for Multiple Myeloma Assessment by Product Type
  • CAR T-Cell Therapy for Multiple Myeloma By Stage and Product Type
  • CAR T-Cell Therapy for Multiple Myeloma Assessment by Route of Administration
  • CAR T-Cell Therapy for Multiple Myeloma By Stage and Route of Administration
  • CAR T-Cell Therapy for Multiple Myeloma Assessment by Molecule Type
  • CAR T-Cell Therapy for Multiple Myeloma by Stage and Molecule Type

 

DelveInsight’s CAR T-Cell Therapy for Multiple Myeloma Report covers around 5+ products under different phases of clinical development like-

  • Late-stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I)
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

 

Some of the key companies in the CAR T-Cell Therapy for Multiple Myeloma Therapeutics Market include:

Key companies developing therapies for CAR T-Cell Therapy for Multiple Myeloma are – Sorrento Therapeutics, Cartesian Therapeutics, CASI Pharmaceuticals, Novartis, Poseida Therapeutics, Shanghai Unicar-Therapy Bio-medicine Technology, Sinobioway Cell Therapy Co., Ltd., Gilead Sciences, Tessa Therapeutics, Wuhan Bio-Raid Biotechnology, Autolus Limited, Beijing Immunochina Medical Science and Technology, BioAtla, BioInvent International, Carsgen Therapeutics, Chongqing Precision Biotech, Eureka Therapeutics, Formula Pharmaceuticals, Guangzhou Bio-gene Technology, Hebei Senlang Biotechnology, Mustang Bio, MolMed, Aurora BioPharma, Atara Biotherapeutics, Bellicum Pharmaceuticals, Kecellitics Biotech Company Ltd, Yake Biotechnology, Minerva Biotechnologies, Shanghai GeneChem Co., Ltd., Allogene Therapeutics, Miltenyi Biotec, PersonGen BioTherapeutics (Suzhou), Precision BioSciences, Takara Bio, BioNTech, Miltenyi Biomedicine, CRISPR Therapeutics, Celgene, Cellectis, Celyad, Gracell Bio, Servier, Protheragen, Noile-Immune Biotech, Arcellx Inc, HRAIN Biotechnology, Tmunity Therapeutics Inc., AffyImmune Therapeutics, Maxcyte, Kuur Therapeutics, TILT Biotherapeutics,Targazyme, TC BioPharm, Takeda, Sensei Biotherapeutics, Sana Biotechnology, Oncternal Therapeutics, Humorigin, Fate Therapeutics, Enlivex Therapeutics Ltd, Exuma, Caribou Biosciences, Arbele Limited, Adicet Bio, and others.

 

Emerging CAR T-Cell Therapy for Multiple Myeloma Drugs Under Different Phases of Clinical Development Include:

  • SG295: Sana Biotechnology
  • GPC2 CAR-T: Tmunity Therapeutics
  • CYAD-203: Celyad Oncology
  • UCART123: Cellectis
  • CTX110: CRISPR Therapeutics
  • JNJ-68284528: Janssen Biotech
  • PHE 885: Novartis Pharmaceuticals
  • CAR-GPC3: Carsgen Therapeutics
  • AUTO4: Autolus Limited
  • ET140202: Eureka Therapeutics
  • Zevorcabtagene autoleucel: CARsgen Therapeutics
  • BPX-601: Bellicum Pharmaceuticals
  • TT11: Tessa Therapeutics
  • CNCT19: CASI Pharmaceuticals
  • Descartes-08: Cartesian Therapeutics
  • MB-CART2019.1: Miltenyi Biomedicine
  • CT 103A: IASO Biotherapeutics

 

Get a Free Sample PDF Report to know more about CAR T-Cell Therapy for Multiple Myeloma Pipeline Therapeutic Assessment- https://www.delveinsight.com/sample-request/car-t-cell-therapy-for-multiple-myeloma-pipeline-insight

 

CAR T-Cell Therapy for Multiple Myeloma Pipeline Analysis:

The CAR T-Cell Therapy for Multiple Myeloma pipeline report provides insights into 

  • The report provides detailed insights about companies that are developing therapies for the treatment of CAR T-Cell Therapy for Multiple Myeloma with aggregate therapies developed by each company for the same.
  • It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for CAR T-Cell Therapy for Multiple Myeloma Treatment.
  • CAR T-Cell Therapy for Multiple Myeloma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
  • CAR T-Cell Therapy for Multiple Myeloma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
  • Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the CAR T-Cell Therapy for Multiple Myeloma market.

The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.

 

Further CAR T-Cell Therapy for Multiple Myeloma product details are provided in the report. Download the CAR T-Cell Therapy for Multiple Myeloma pipeline report to learn more about the emerging CAR T-Cell Therapy for Multiple Myeloma therapies

 

CAR T-Cell Therapy for Multiple Myeloma Pipeline Market Drivers

  • Increased Collaborations and Acquisitions
  • Wide range of targets and indications
  • Increased clinical and preclinical studies with positive results

 

CAR T-Cell Therapy for Multiple Myeloma Pipeline Market Barriers

  • Scalability and cost to ensure accessibility and affordability
  • Technological barriers
  • Optimization of dosing and toxicity concerns

 

Scope of CAR T-Cell Therapy for Multiple Myeloma Pipeline Drug Insight    

  • Coverage: Global
  • Key CAR T-Cell Therapy for Multiple Myeloma Companies: Sana Biotechnology, Tmunity Therapeutics, Celyad Oncology, Cellectis, CRISPR Therapeutics, Carsgen Therapeutics, Autolus Limited, Eureka Therapeutics, CARsgen Therapeutics, Bellicum Pharmaceuticals, Tessa Therapeutics, CASI Pharmaceuticals, Cartesian Therapeutics, Miltenyi Biomedicine, and others
  • Key CAR T-Cell Therapy for Multiple Myeloma Therapies: SG295, GPC2 CAR-T, CYAD-203, UCART123, CTX110, CAR-GPC3, AUTO4, ET140202, Zevorcabtagene autoleucel, BPX-601, TT11, CNCT19, Descartes-08, MB-CART2019.1, and others
  • CAR T-Cell Therapy for Multiple Myeloma Therapeutic Assessment: CAR T-Cell Therapy for Multiple Myeloma current marketed and CAR T-Cell Therapy for Multiple Myeloma emerging therapies
  • CAR T-Cell Therapy for Multiple Myeloma Market Dynamics: CAR T-Cell Therapy for Multiple Myeloma market drivers and CAR T-Cell Therapy for Multiple Myeloma market barriers 

 

Request for Sample PDF Report for CAR T-Cell Therapy for Multiple Myeloma Pipeline Assessment and clinical trials

 

Table of Contents

1

CAR T-Cell Therapy for Multiple Myeloma Report Introduction

2

CAR T-Cell Therapy for Multiple Myeloma Executive Summary

3

CAR T-Cell Therapy for Multiple Myeloma Overview

4

CAR T-Cell Therapy for Multiple Myeloma- Analytical Perspective In-depth Commercial Assessment

5

CAR T-Cell Therapy for Multiple Myeloma Pipeline Therapeutics

6

CAR T-Cell Therapy for Multiple Myeloma Late Stage Products (Phase II/III)

7

CAR T-Cell Therapy for Multiple Myeloma Mid Stage Products (Phase II)

8

CAR T-Cell Therapy for Multiple Myeloma Early Stage Products (Phase I)

9

CAR T-Cell Therapy for Multiple Myeloma Preclinical Stage Products

10

CAR T-Cell Therapy for Multiple Myeloma Therapeutics Assessment

11

CAR T-Cell Therapy for Multiple Myeloma Inactive Products

12

Company-University Collaborations (Licensing/Partnering) Analysis

13

CAR T-Cell Therapy for Multiple Myeloma Key Companies

14

CAR T-Cell Therapy for Multiple Myeloma Key Products

15

CAR T-Cell Therapy for Multiple Myeloma Unmet Needs

16 

CAR T-Cell Therapy for Multiple Myeloma Market Drivers and Barriers

17

CAR T-Cell Therapy for Multiple Myeloma Future Perspectives and Conclusion

18

CAR T-Cell Therapy for Multiple Myeloma Analyst Views

19

Appendix

20

About DelveInsight

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

 

Download Sample PDF Report to know more about CAR T-Cell Therapy for Multiple Myeloma drugs and therapies

Media Contact
Company Name: DelveInsight Business Research
Contact Person: Gaurav Bora
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting


Posted

in

by

Tags: